ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 11/23/21

Danish pharmaceutical giant, Novo Nordisk (NYSE: NVO) made a lot of headlines recently with a big buyout offer for Dicerna Pharmaceuticals (NASDAQ: DRNA) . Novo Nordisk offered Dicerna shareholders a great big 80% premium , leading investors to wonder which biotech stock...

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2021 Earnings Conference Call November 22, 2021, 04:30 PM ET Company Participants Vince Anzalone - VP, IR Christopher Anzalone - President and CEO Javier San Martin - Chief Medical Officer Ken Myszkowski - CFO James Hamilton - SVP, Discovery and Trans...

Image source: The Motley Fool. Arrowhead Pharmaceuticals, inc (NASDAQ: ARWR) Q4 2021 Earnings Call Nov 22, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Arrowhead Pharmaceuticals, inc (ARWR) Q4 2021 Earnings Call ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR): FY GAAP EPS of -$1.36 misses by $0.77. Revenue of $138.29M (+57.2% Y/Y) misses by $35.61M. Press Release For further details see: Arrowhead Pharmaceuticals EPS misses by $0.77, misses on revenue

- Conference Call and Webcast Today, November 22, 2021 at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2021. The company is hosting a conference call today, November 22, 2021, at 4:30 p.m. E...

- Upon closing, Arrowhead to receive $120 million upfront payment for Phase 1/2 program for NASH - Arrowhead eligible to receive potential milestone payments and royalties on commercial sales - GSK to receive an exclusive license for ARO-HSD in all territories except Greater Chi...

A, ADMP, AESE, ARWR, BBIG, CANG, ELYS, ENTA, JACK, KEYS, RMAX, URBN, ZM For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Monday's close

Recent Acquisition of RNAi drug maker Dicerna by Novo Nordisk makes a case for eventual partnership/buyout of Arbutus Biopharma. AB-729 has proven to work in treating patients with Hepatitis B with significant Hepatitis B surface antigen reduction alone. Four triple combinations studi...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is scheduled to announce FY earnings results on Monday, November 22nd, after market close. The consensus EPS Estimate is -$0.67 (+20.2% Y/Y) and the consensus Revenue Estimate is $173.9M (+97.6% Y/Y). Over the last 3 months, EPS estimates have seen 2 up...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...